Regen BioPharma, Inc. (RGBPP) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en La Mesa, CA, United States. El CEO actual es David Raymond Koos.
RGBPP tiene fecha de IPO 2016-04-20, 1 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $193.98K.
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is in the early stages of development of its products, and therapies. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California.
